Recombinant transgelin-2 protein, engineered for cell-penetration and de-ubiquitination, potentiated DC functions to suppress tumor growth and metastasis, demonstrating that this small-actin binding protein represents a promising therapeutic approach for DC-based cancer immunotherapy. This evidence concerns the gene TAGLN2 and neoplasm.